A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers. (FANTASY)
A Randomized, Double-Blind, 3-arm Parallel Study to Compare PK, Safety, IMM and Tolerability of MB05, EU-sourced Synagis® and US-sourced Synagis®, as a Single Dose Intramuscular Injection in Healthy Volunteers.
Sponsor: mAbxience Research S.L.
This PHASE1 trial investigates Healthy Volunteers and is currently completed. mAbxience Research S.L. leads this study, which shows 11 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — May 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Jul 2022 — Nov 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- mAbxience Research S.L.
For direct contact, visit the study record on ClinicalTrials.gov .